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This research communication reports interferences related to the administration of ivermectin 24 
in lactating dairy goats on the response of microbial tests for screening antibiotics in milk. 25 
Twenty-eight Murciano-Granadina goats, naturally infested with Sarcoptes scabiei var. 26 
caprae, were treated with a subcutaneous injection of ivermectin (200 µg/Kg b.w.). To 27 
prevent re-infestation, a second dose was applied seven days later. Individual milk samples 28 
were collected, daily, up to fifteen days post-treatment. Milk samples were analysed by 29 
microbial inhibitor tests (BRT MRL, Delvotest SP-NT MCS and Eclipse 100) and ivermectin 30 
residues were quantified by HPLC. A large number of positive results were obtained for all 31 
the microbial tests, especially on the first day after treatment (BRT MRL= 46.4%; Delvotest 32 
SP-NT MCS= 14.3%; and Eclipse 100= 17.8%). However, the highest concentration of drug 33 
residues in milk (24.3 ng/ml) was detected on the tenth day after treatment, when positive 34 
outcomes were relatively lower (BRT MRL= 17.8%; Delvotest SP-NT MCS= 10.7%; and 35 
Eclipse 100= 7.4%). Results herein suggest that factors related to the ivermectin treatment 36 
other than drug residues in milk, or alterations produced by the parasitic disease itself 37 
affecting the immune response of animals, could be the cause of false-positive results in 38 
microbial tests. It can be concluded that the application of ivermectin in dairy goats infested 39 
3 
 
with sarcoptes mange during lactation produces persistent drug residues in milk, and could 40 
also cause false-positive results in microbial tests for screening antibiotics. 41 
Key words: goat milk, ivermectin, microbial inhibitor tests 42 
Monitoring the presence of antibiotic residues above the maximum residue limits (MRLs) in 43 
foodstuffs of animal origin is mandatory in the European Union (Regulation (EC) No 44 
853/2004). Microbial inhibitor tests are widely used for screening antibiotics in raw milk as 45 
they are relatively inexpensive, user-friendly and have a high sample throughput. However, 46 
they are non-specific and several factors related to milk composition (natural inhibitors or 47 
somatic cell counts, among others), have been associated with the occurrence of false 48 
positive results (Andrew, 2001; Althaus et al., 2003). Also, the presence of contaminants in 49 
milk related to regular farming practices (detergents, disinfectants or antiparasitic 50 
substances) may interfere with the microbial test responses (Romero et al., 2014; 2015). 51 
However, available information about this aspect is rather limited. 52 
Antiparastic treatments are often applied to prevent and control various parasitic diseases. 53 
Sarcoptic mange, caused by the ectoparasite Sarcoptes scabiei var. caprae, is a common 54 
parasitic disease in caprine livestock causing considerable economic losses as milk 55 
production is decreased (Wallton & Currie, 2007). Additionally, it can have repercussions on 56 
public health because of its potential transmission; therefore the antiparasitic treatment of 57 
goats infested with sarcoptic mange becomes necessary. 58 
Ivermectin (IVM) is one of the most effective drugs against scabies and other parasitic 59 
diseases (McKellar & Benchaoui, 1996). However, its use is not authorised in animals from 60 
which milk is produced for human consumption (Commission Regulation (EU) No 37/2010) 61 
due to the high persistence of IVM residues in milk (Alvinerie et al., 1993; Fernanda et al., 62 
2004). Accordingly, the MRL for this substance in milk has not been established and, 63 
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therefore, the health impact of the illegal use of this drug in lactating dairy goats in unknown. 64 
The European Medicine Agency (EMA, 2014) indicates that the Codex Alimentarius 65 
establishes an MRL for IVM residues in milk at a concentration of 10 µg/kg, although more 66 
studies about its potential effects are necessary to set the MRL in the European legislation. 67 
The aim of this study was to evaluate the response of microbial inhibitor tests in milk from 68 
dairy goats treated with IVM during lactation. 69 
Material and methods 70 
Animals, antiparasitic treatment and milk sampling 71 
Twenty-eight Murciano-Granadina goats in the fifth month of lactation (body weight 55-65 72 
kg) from the Institute of Animal Science and Technology of Universitat Politècnica de 73 
València (UPV, Valencia, Spain) were used. Animal procedures and management were 74 
approved by the Ethics Committee of UPV. 75 
Animals naturally infested with sarcoptic mange were treated with Ivomec (Merial 76 
Laboratorios S.A., Madrid, Spain; IVM 1.0%) by subcutaneous injection following the 77 
manufacturer's recommendations for ovine species. The dose administered was 0.2 ml/10 kg 78 
b.w. (200 μg of IVM per kg b.w.). To prevent re-infestation, a second dose was applied 79 
seven days after the first treatment. 80 
The animals were milked in a milking parlour (08:00 a.m.) and the sampling was carried out 81 
for 15 days after the first administration. Milk samples were analysed by microbial screening 82 
tests and aliquots were frozen (-80 °C) for ivermectin quantification by HPLC. 83 
Microbial inhibitor tests 84 
Goat’s milk samples were analysed in triplicate by microbial inhibitor tests: BRT MRL 85 
(Analytik in MilchProduktions-und Vertriebs-GmbH, Munich, Germany), Delvotest SP-NT 86 
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MCS (DSM Food Specialties, Delft, Netherlands) and Eclipse 100 (ZEULAB S.L., 87 
Zaragoza, Spain). The tests were used according to each manufacturer’s instructions. A 88 
negative control (antimicrobial-free goat milk) and a positive control (antimicrobial-free goat 89 
milk spiked with 4 μg/kg of benzylpenicillin) were included on each plate. Visual 90 
interpretation of the test results was carried out by three technicians assessing the colour 91 
change in the medium; classifying milk samples as “positive” when the colour remained 92 
purple/blue and “negative” when the colour changed to yellow. 93 
Ivermectin quantification 94 
Extraction and derivatisation procedures to quantify IVM were carried out following the 95 
technique described by Imperiale et al. (2004). IVM was analysed using a Waters HPLC 96 
system (Milford, MA, USA), which included two pumps (Mod. 515, Waters), an 97 
autosampler (Mod. 717 plus, Waters), and a fluorescence detector (Mod. 474, Waters) set at 98 
an excitation and emission wavelength of 365 and 475 nm, respectively. The separation in 99 
isocratic form was achieved using a Nova-Pack C18 column (Waters, 4 µm, 3.9x150 mm) 100 
coupled with a guard column Nova-Pack C18 (3.9x2 mm) at 35 ºC. The mobile phase 101 
consisted of a methanol/water mix (97:3, v/v) using a flow rate of 1.8 ml/min. IVM was 102 
identified by comparison with retention time of a reference standard and IVM concentration 103 
was calculated using an internal standard (abamectin, ABM). The standards of IVM (I8898) 104 
and ABM (31732) were provided by Sigma-Aldrich (Sigma-Aldrich Química, S.A., Madrid, 105 
Spain). The detection limit (LOD) and the quantification limit (LOQ) calculated for IVM 106 
were 0.13 ng/ml and 0.43 ng/ml, respectively. Average ivermectin recovery was 92.7% and 107 




The non-parametric Kruskal-Wallis test (K-W) was applied to analyse statistical differences 110 
(P <0.05) of IVM concentrations with respect to days post-treatment. Subsequently, the 111 
Bonferroni test was performed to establish the differences along the days post-treatment. 112 
Statgraphics Centurion XVI software (16.1.03) (StatPoint Technologies, Inc., Warrenton, 113 
VA, USA) was used for statistical analyses. 114 
Results and discussion 115 
As shown in Table 1, a large number of positive outcomes were obtained when antibiotic-116 
free milk samples from goats treated with IVM were analyzed. Although the occurrence of 117 
positive results was observed throughout most of the experimental period (up to 14 days), the 118 
highest percentage was recorded, in all cases, on the first day post-treatment (BRT MRL= 119 
46.4%; Delvotest SP-NT MCS= 14.3%; and Eclipse 100= 17.8%), the BRT MRL being the 120 
most affected test throughout the experimental period. These results could be related to the 121 
different composition of the culture medium of the tests (BRT MRL: Mueller-Hinton agar 122 
and black brilliant as redox indicator; Delvotest SP-NT MCS and Eclipse 100: Plate count 123 
agar and bromocresol purple as pH indicator). 124 
Microbial screening tests present a lower false-positive rate (0.6-4.3%) in milk from 125 
individual goats (Beltrán et al., 2015) and, therefore, results obtained herein suggest that the 126 
administration of IVM may be related to these interferences. 127 
A significant increase (p<0.05) of the concentration of IVM residues in goat’s milk along the 128 
three days following the application of the drug (Figure 1) was observed. However, the 129 
concentration of IVM ranged from 8.9 to 24.3 ng/ml, values rather lower than the inhibitory 130 
concentration producing 5% of positive results in microbial tests (IC5) calculated by Romero 131 
et al. (2015) in an in vitro study (BRT MRL= 41 mg/l; Delvotest SP-NT MCS= 83 mg/l and 132 
Eclipse 100= 109 mg/l). In addition, the highest occurrence of positive results was not related 133 
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to an elevated concentration of IVM residues in milk, suggesting that factors associated to 134 
drug administration other than residues in milk could be the cause of the interferences found. 135 
Thus, for example, IVM has been evaluated as immunomodulatory showing a favourable 136 
potential use as positive modulator (Stankiewwicz et al., 1995; Sajid et al., 2007). Moreover, 137 
several studies indicate that sarcoptes mange does not only produce visible dermatological 138 
symptoms in mite-infested goats, but is also associated with physiological changes such as 139 
highest concentration of biochemical indicators of oxidative stress in the blood (Ujival Dey, 140 
2010), high total protein levels, γ-globulin and IgG in the serum plasma (Lastras et al., 2000), 141 
and increased pro-inflammatory cytokine levels (Mullins et al. 2009) as well as high levels of 142 
acute phase proteins in the blood (Rahman et al., 2010). The potential changes in the 143 
immunological system of the animals as a result of the IVM activity or the immune response 144 
of goats to combat the parasitic disease, could result in the presence of inhibitory substances 145 
in milk capable of interfering with the response of microbial inhibitor tests for screening 146 
antibiotics. 147 
It can be concluded that the illegal application of IVM in lactating dairy goats infested with 148 
sarcoptes mange produces persistent drug residues in milk and could also cause false-positive 149 
results in microbial inhibitor tests for screening antibiotics. 150 
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Positive results (%) 
BRT MRL Delvotest SP- NT MCS Eclipse 100 
1 46.4  14.3 17.8 
2 32.1 7.4 7.4 
3 25.0 3.6 10.7 
4 21.4 7.4 3.6 
5 28.6 10.7 10.7 
6 7.4 10.7 7.4 
7 3.6 10.7 3.6 
8 35.7 10.7 3.6 
9 32.1 7.4 7.4 
10 17.8 10.7 7.4 
11 10.7 7.4 3.6 
12 14.3 0.0 3.6 
13 14.3 0.0 0.0 
14 10.7 0.0 0.0 
15 0.0 0.0 0.0 












Figure 1. Box and whisker plots illustrating the concentration of ivermectin (IVM) in 236 
goat milk on the post-treatment days. The plots show the 25th and 75th percentiles (box), 237 
median (—), mean (+), 10th and 90th percentiles (whisker bars) and outliers (□). 238 
Dose 2 Dose 1 
